WTA
EBS icon

Washington Trust Advisors’s Emergent Biosolutions EBS Stock Holding History

Washington Trust Advisors’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-91
Closed -$4K – 1005
2021
Q4 		$4K Buy
+91
New +$4.12K ﹤0.01% 879

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Washington Trust Advisors's EBS Position: Q1 2022 in Review

Washington Trust Advisors sold out of Emergent Biosolutions (EBS) in Q1 2022, closing a stake of 91 shares — an estimated $4K sold.

Washington Trust Advisors first reported a position in EBS in Q4 2021 and held it in 1 quarter. The position peaked at $4K in Q4 2021. 255 funds tracked by Wall St. Rank hold EBS as of Q1 2022.

  • Washington Trust Advisors reported no remaining Emergent Biosolutions position as of Q1 2022 after selling out during the quarter.
  • Washington Trust Advisors sold 91 Emergent Biosolutions shares in Q1 2022, an estimated $4K.
  • Washington Trust Advisors first reported a position in Emergent Biosolutions in Q4 2021 and held it in 1 quarter.
  • Washington Trust Advisors's Emergent Biosolutions position peaked at $4K in Q4 2021.
  • 255 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2022.

Based on Washington Trust Advisors's 13F filing for Q1 2022, filed 5 May 2022.